Glacier Bancorp Inc. (GBCI) Drops 5.2% on January 13

Equities Staff |

Glacier Bancorp Inc. (GBCI) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 5.2% to $23.01, a loss of $-1.262 per share. Starting at an opening price of $24.27 a share, the stock traded between $22.75 and $24.47 over the course of the trading day. Volume was 405,202 shares over 5,220 trades, against an average daily volume of 436,359 shares and a total float of 76.09 million.

The losses send Glacier Bancorp Inc. down to a market cap of $1.75 billion. In the last year, Glacier Bancorp Inc. has traded between $30.29 and $22.16, and its 50-day SMA is currently $27.08 and 200-day SMA is $26.75.

The stock has a P/E Ratio of 16.

Glacier Bancorp Inc is a regional bank holding company. The Company offers banking products and services, including transaction and savings deposits, real estate, commercial, agriculture and consumer loans and mortgage origination services.

Glacier Bancorp Inc. is based out of Kalispell, MT and has some 2,030 employees. Its CEO is Michael J. Blodnick.

For a complete fundamental analysis analysis of Glacier Bancorp Inc., check out’s Stock Valuation Analysis report for GBCI. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets


Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…


Spotify is a online music service offering providing digital content from a range of record labels and artists. Users can browse through the interface by artist, album, genre, playlist, record…